AI brief of an SEC Form 8-K · CAPRICOR THERAPEUTICS, INC. (CAPR)

Capricor Therapeutics FDA panel votes 9-3 against Deramiocel for DMD cardiomyopathy

Negative Impact 4 of 5 legal/regulatory Written later

An FDA advisory committee voted on July 29, 2026 that available evidence did not support the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy patients. The vote is non-binding, and the FDA will consider it in its ongoing review of the Biologics License Application, whose PDUFA target action date remains August 22, 2026.

Key points

Committee vote on July 29, 2026 was 3 for, 9 against and 0 abstaining
The Committee's recommendation is non-binding; the FDA will weigh it with the full administrative record
PDUFA target action date for the BLA remains August 22, 2026
In a separate upper limb function discussion, the Committee's feedback was directionally supportive of Phase 3 HOPE-3 data, including the PUL 2.0 primary endpoint

The filing

CompanyCAPRICOR THERAPEUTICS, INC. (CAPR)

Form8-K, current report

Filed with the SECJul 30, 2026, 4:05 PM ET

Accession number0001104659-26-088667

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.